Brief: FDA Accepts Krystal Biotech's BLA For Dystrophic Epidermolysis Bullosa
18/08/2022 22:20
Aug 18 (Reuters) - Krystal Biotech Inc KRYS.O :
* FDA ACCEPTS KRYSTAL BIOTECH’S BIOLOGICS LICENSE
APPLICATION FOR
DYSTROPHIC EPIDERMOLYSIS BULLOSA
* KRYSTAL BIOTECH INC - PDUFA TARGET ACTION DATE IS FEBRUARY
17,
2023
* KRYSTAL BIOTECH INC - FDA STATED THAT IT IS NOT CURRENTLY
PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING
Source text for Eikon: ID:nGNX4kyyCT
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion